Published in Virol J on March 08, 2010
Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol (2011) 1.23
Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS (2011) 1.22
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gene Ther (2013) 0.93
RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics (2006) 87.59
BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol (2007) 74.13
RAxML-III: a fast program for maximum likelihood-based inference of large phylogenetic trees. Bioinformatics (2004) 20.94
Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol (2005) 18.57
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol (2007) 3.64
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
Causes of HIV diversity. Nature (1995) 2.48
The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol (2005) 1.76
First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica (2007) 0.96
Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev (2005) 0.95
Divergence of HIV-1 quasispecies in an epidemiologic cluster. AIDS (1997) 0.88
V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV. PLoS One (2009) 0.85
Reappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment interruption. Scand J Infect Dis (2008) 0.82
Virus load and antigenic diversity. Bull Math Biol (1997) 0.80
Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype. J Med Virol (2008) 0.78
Treatment interruption in chronic HIV-1 infection: does it deliver? Curr Opin HIV AIDS (2007) 0.78
Reactivation of ancestral strains of HIV-1 in the gp120 V3 env region in patients failing antiretroviral therapy and subjected to structured treatment interruption. Virology (2006) 0.78
Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol (2007) 3.64
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis (2011) 2.60
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS (2010) 1.83
CAIcal: a combined set of tools to assess codon usage adaptation. Biol Direct (2008) 1.77
Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder. Neuroimage (2007) 1.71
Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr (2010) 1.65
Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol (2008) 1.63
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis (2011) 1.53
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
E-CAI: a novel server to estimate an expected value of Codon Adaptation Index (eCAI). BMC Bioinformatics (2008) 1.43
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol (2012) 1.41
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr (2012) 1.38
Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill (2004) 1.29
Papillomaviruses: different genes have different histories. Trends Microbiol (2005) 1.27
Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med (2014) 1.22
The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol (2013) 1.21
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis (2007) 1.18
Selective gene silencing by viral delivery of short hairpin RNA. Virol J (2010) 1.17
Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med (2016) 1.15
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res (2010) 1.13
Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS (2012) 1.12
Multiple evolutionary mechanisms drive papillomavirus diversification. Mol Biol Evol (2007) 1.10
Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill (2004) 1.10
Quantifying the phylodynamic forces driving papillomavirus evolution. Mol Biol Evol (2011) 1.08
The highly conserved orthopoxvirus 68k ankyrin-like protein is part of a cellular SCF ubiquitin ligase complex. Virology (2008) 1.08
Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J Gen Virol (2006) 1.03
An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol (2012) 1.02
Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak (2011) 0.99
Bichat guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill (2004) 0.98
Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol (2009) 0.98
Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology (2007) 0.98
HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology (2012) 0.97
The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J Gen Virol (2003) 0.97
Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. Euro Surveill (2004) 0.97
Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol (2007) 0.96
Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infect Agent Cancer (2011) 0.95
Cue reactivity and its inhibition in pathological computer game players. Addict Biol (2012) 0.94
Genomic characterization of the first insectivoran papillomavirus reveals an unusually long, second non-coding region and indicates a close relationship to Betapapillomavirus. J Gen Virol (2009) 0.93
Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine (2012) 0.93
Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites. Retrovirology (2011) 0.93
High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol (2011) 0.92
Different papillomaviruses have different repertoires of transcription factor binding sites: convergence and divergence in the upstream regulatory region. BMC Evol Biol (2006) 0.92
Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system. PLoS One (2013) 0.89
Novel animal papillomavirus sequences and accurate phylogenetic placement. Mol Phylogenet Evol (2012) 0.89
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One (2011) 0.89
Characterization of novel cutaneous human papillomavirus genotypes HPV-150 and HPV-151. PLoS One (2011) 0.89
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol (2009) 0.89
Human APOBEC3G incorporation into murine leukemia virus particles. Virology (2005) 0.89
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother (2007) 0.88
The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol J (2007) 0.88
Bichat guidelines for the clinical management of plague and bioterrorism-related plague. Euro Surveill (2004) 0.88
Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Euro Surveill (2004) 0.87
A novel rodent papillomavirus isolated from anogenital lesions in its natural host. Virology (2008) 0.87
Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells. Virology (2002) 0.87
Bichat guidelines for the clinical management of Q fever and bioterrorism-related Q fever. Euro Surveill (2004) 0.86
Murine leukemia virus (MLV) replication monitored with fluorescent proteins. Virol J (2004) 0.86
HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization. PLoS One (2013) 0.85
The evolution of Dscam genes across the arthropods. BMC Evol Biol (2012) 0.85
V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV. PLoS One (2009) 0.85
Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol (2014) 0.85
In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. J Virol Methods (2010) 0.85
Evolution in regulatory regions rapidly compensates the cost of nonoptimal codon usage. Mol Biol Evol (2010) 0.85
Establishment of a mouse xenograft model for mycosis fungoides. Exp Dermatol (2004) 0.84
Novel papillomaviruses in free-ranging Iberian bats: no virus-host co-evolution, no strict host specificity, and hints for recombination. Genome Biol Evol (2014) 0.84
Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. J Vis Exp (2011) 0.84
APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1. Med Microbiol Immunol (2011) 0.83
Multiple independent kinase cascades are targeted by hyperosmotic stress but only one activates stress kinase p38. Exp Cell Res (2004) 0.83
Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma. Mod Pathol (2013) 0.82
Modified envelope glycoproteins to retarget retroviral vectors. Curr Gene Ther (2003) 0.82
Stable integration of a functional shRNA expression cassette into the murine leukemia virus genome. Virology (2006) 0.82
Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells. Virus Res (2007) 0.81
Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood (2011) 0.81
The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth. Virol J (2008) 0.80
Methylation of human papillomavirus Type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR. J Clin Microbiol (2013) 0.80
HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G. Curr HIV Res (2005) 0.80
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer (2013) 0.80
Vaccinia virus replication is not affected by APOBEC3 family members. Virol J (2006) 0.80
Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases. J Virol (2011) 0.79
Meeting report: primary central nervous system lymphoma: standards of care and future perspectives. Onkologie (2005) 0.79
Replacement of the murine leukemia virus (MLV) envelope gene with a truncated HIV envelope gene in MLV generates a virus with impaired replication capacity. Virology (2003) 0.79
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078. Antiviral Res (2012) 0.79
Transport of N-acetyl-D-mannosamine and N-acetyl-D-glucosamine in Escherichia coli K1: effect on capsular polysialic acid production. FEBS Lett (2002) 0.78
Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype. J Med Virol (2008) 0.78
Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells. Anticancer Res (2012) 0.78
Feline foamy virus-mediated marker gene transfer: identification of essential genetic elements and influence of truncated and chimeric proteins. Virology (2006) 0.78
Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill (2004) 0.78
Specific transduction of HIV-1 envelope expressing cells by retroviral vectors pseudotyped with hybrid CD4/CXCR4 receptors. J Virol Methods (2002) 0.77
HIV-1 mutational pathways under multidrug therapy. AIDS Res Ther (2011) 0.77
Cutaneous T-cell lymphoma cells are sensitive to rapamycin. Exp Dermatol (2010) 0.77
Identification and characterization of equine granzyme B. Vet Immunol Immunopathol (2007) 0.77
Bichat guidelines for the clinical management of smallpox and bioterrorism-related smallpox. Euro Surveill (2004) 0.76
Multiple evolutionary origins of bat papillomaviruses. Vet Microbiol (2013) 0.76